（文章来源：证券日报） 证券日报网讯 9月22日晚间，泰恩康发布公告称，截至2025年9月22日，公司2025年员工持股计划（简 称"本持股计划"）已通过二级市场集中竞价方式累计买入公司股票5，396，243股，占公司总股本的 1.27%，成交金额合计197，967，478.50元（不含交易费用），成交均价为36.69元/股。本持股计划实际 认购份额未超过公司股东大会审议通过的拟认购份额上限，公司已完成本持股计划标的股票的购买。 ...

2025年9月22日，广东泰恩康医药股份有限公司（证券代码：301263，证券简称：泰恩康）发布公告， 宣布公司2025年员工持股计划已顺利完成股票购买，充分彰显对未来经营发展的坚定信心。 据悉，泰恩康于2025年8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相 关议案，为计划落地奠定坚实基础。截至2025年9月22日，该计划通过二级市场集中竞价方式，累计买 入公司股票539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均 价36.69元/股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 公司董事长郑汉杰先生表示："员工持股计划圆满落地，是公司'以人为本、共享发展'理念的生动实 践。员工对公司未来战略前景的高度认同与坚定信心，是公司最宝贵的财富和无形的驱动力。我们将持 续聚焦核心战略，提升经营效能，以更亮眼的成绩回报全体股东的信任。" 泰恩康此次员工持股计划的顺利落地，极大激发了创新活力与奋斗激情，为后续业务拓展、技术创新注 入更强动力，为实现高质量发展奠定坚实基础。该计划的成功实施，有望成为驱动泰恩康实现新一轮高 质 ...

格隆汇9月22日丨泰恩康(301263.SZ)公布，截至2025年9月22日，2025年员工持股计划已通过二级市场 集中竞价方式累计买入公司股票5,396,243股，占公司总股本的1.27%，成交金额合计197,967,478.50元 （不含交易费用），成交均价为36.69元/股。本持股计划实际认购份额未超过公司股东大会审议通过的 拟认购份额上限。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-067 广东泰恩康医药股份有限公司 关于 2025 年员工持股计划完成股票购买的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 1、公司控股股东、实际控制人未参加本员工持股计划，本员工持股计划未 与公司控股股东、实际控制人签署一致行动协议或存在一致行动安排。 2、公司部分董事（不含独立董事）、高级管理人员持有本员工持股计划份 额，在公司股东大会、董事会审议本员工持股计划相关提案时相关人员均均回 避表决。本员工持股计划未与公司董事、高级管理人员签署一致行动协议或存 在一致行动安排。 3、持有人会议为本员工持股计划的最高权利机构，持有人会议选举产生管 理委员会，监督本员工持股计划的日常管理，本员工持股计划持有人持有的份 额相对分散，任意单一持有人均无法对持有人会议及管理委员会决策产生重大 影响。 广东泰恩康医药股份有限公司（以下简称"公司"）分别于 2025 年 8 月 4 日、2025 年 8 月 20 日召开了第五届董事会第九次会议、第五届监事会第九次会 议及 2025 年第一次临时股东大会，审 ...

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Core Viewpoint - The company held an investor meeting to discuss new drug development, dividend plans, and profit enhancement strategies, highlighting its commitment to innovation and shareholder returns [1]. New Drug Development Progress - Investors showed significant interest in the company's new drug development, particularly the Phase III clinical trial for CKBA targeting vitiligo, which is expected to start by the end of 2025 [2]. - The IIT study for vitiligo in children aged 2-12 is progressing steadily, with data expected to be released in Q4 of this year [2]. - The company plans to initiate clinical trials for CKBA in treating rosacea as soon as it receives the II/III seamless adaptive trial approval [2]. - CKBA is positioned as a first-in-class innovative small molecule drug with substantial potential in autoimmune diseases, with plans to expand research into multiple indications [2]. - The company will keep stakeholders updated on drug approval progress and will consider orphan drug application requirements for CKBA if it proves effective and safe for children [2]. Dividend and Profit Planning - The company confirmed a stable cash dividend policy, announcing a plan to distribute 2 yuan per 10 shares for the 2024 fiscal year, with future plans to adjust based on actual conditions [3]. - Due to increased market competition, the company reported a decline in revenue and gross margin, leading to short-term performance pressure [3]. - To drive profit growth, the company aims to advance CKBA's clinical trials, launch specialty generic drugs like compound sodium sulfate tablets, and accelerate the domestic production of gastrointestinal medications [3]. Employee Stock Ownership Plan Disclosure - The company is in the stock purchase phase of its employee stock ownership plan, which will be disclosed monthly for six months following shareholder meeting approval [4].

Group 1: Clinical Trials and Research Progress - The company is actively promoting the CKBA clinical trial for vitiligo, aiming to start by the end of 2025 [2] - The IIT study for vitiligo in children aged 2-12 is progressing, with data expected in Q4 of this year [2] - The company plans to initiate clinical trials for CKBA in treating rosacea once the II/III phase trial approval is obtained [3] Group 2: Financial Performance and Dividends - The company has maintained a stable cash dividend ratio, proposing a dividend of 2 CNY per 10 shares for the 2024 fiscal year [4] - Recent increases in R&D investment and declining sales in men's health products have led to short-term performance pressure [5] - The company is focusing on launching high-potential generic drugs to create new profit growth points [5] Group 3: Employee Stock Plan and Disclosure - The employee stock plan will disclose purchase details monthly for six months after approval at the shareholders' meeting [5] - The company is committed to adhering to disclosure regulations regarding the employee stock plan [5] - No undisclosed significant information was revealed during the earnings presentation [6]

Core Viewpoint - The performance of the Zhongzheng 2000 ETF managed by Jiashi Fund has shown a decline in its share price and mixed results among its major holdings since its inception on September 14, 2023 [1] Group 1: ETF Performance - As of the midday close on September 19, the Zhongzheng 2000 ETF Jiashi (159535) decreased by 0.92%, trading at 1.395 yuan with a transaction volume of 453,100 yuan [1] - Since its establishment, the fund has achieved a return of 40.87%, with a monthly return of 1.85% [1] Group 2: Major Holdings Performance - Major stocks within the ETF include: - Meiri Hudong down 0.31% - Hanwei Technology down 7.97% - Hongchuang Holdings up 5.27% - Dongtu Technology down 1.34% - Hengbao Shares down 5.53% - Taiji Shares down 0.72% - Rejing Biology down 4.53% - Shijia Photon up 0.67% - Huasheng Tiancai down 4.24% - Tainkang up 1.49% [1]

Group 1 - Shudao Equipment's subsidiary signed a construction contract worth 24.68 million yuan for a hydrogen fuel cell manufacturing base project [1] - Zhongliang Technology received a land acquisition compensation of 30 million yuan from the government [2] - Palm Holdings won a bid for a high-standard farmland construction project in Lankao County, with a contract value of 433 million yuan, accounting for 14.12% of the company's audited revenue for 2024 [3] Group 2 - Changchun Yidong's subsidiary received a government subsidy of 2.85 million yuan, which is 122.78% of the company's audited net profit for the last fiscal year [4] - Wuzhou Transportation successfully issued 200 million yuan in medium-term notes with an interest rate of 2.10% [5][6] - Tiandi Source's subsidiary plans to apply for a trust loan of up to 500 million yuan from related parties [8] Group 3 - Tiandi Source's subsidiary acquired a residential land use right in Xi'an for 2.015 billion yuan [9] - Opcon Vision received a medical device registration certificate for its ultrasonic nebulizer [11] - Jingjiawei announced the resignation of its vice president due to personal reasons [13] Group 4 - Fulinh Precision's subsidiary received a prepayment of 1.5 billion yuan from CATL for securing lithium iron phosphate material supply [15] - Yunzhu Technology's subsidiary received a government subsidy of 20.12 million yuan [16] - Kehua Bio's ferritin test kit received a medical device registration certificate [17] Group 5 - Jinghua Pharmaceutical's medical sodium alginate wound dressing received a medical device registration certificate [18] - Lingwei Technology established a wholly-owned subsidiary with a registered capital of 1 million yuan [19] - Sanwei Co. won a bid for concrete sleeper procurement projects worth 158 million yuan [20] Group 6 - Shanghai Pharmaceuticals' Nicardipine tablets passed the consistency evaluation for generic drugs [21] - Lushan New Materials increased its idle fund management limit to 750 million yuan [24] - Huayi Technology announced the retirement of a core technical staff member [25] Group 7 - Yingli Environment plans to use up to 300 million yuan of idle raised funds for cash management [30] - Yong'an Forestry plans to develop a national reserve forest project in Putian, Fujian, with an estimated investment of 154 million yuan [32] - Xinyuan Technology's shareholders plan to reduce their holdings by up to 3.18% of the company's shares [60]

Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its drug approval process [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The acceptance of the application is based on the review conducted by the NMPA according to Article 32 of the Administrative Licensing Law of the People's Republic of China [1] Group 2: Product Information - Safinamide Mesylate Tablets are a selective inhibitor of monoamine oxidase B (MAO-B) and are primarily used for treating adult patients with idiopathic Parkinson's disease (PD) [1] - The drug serves as an adjunct therapy to stable doses of Levodopa (L-dopa) alone or in combination with other PD treatments for patients experiencing mid to late-stage fluctuations [1]